Le Lézard
Classified in: Health
Subjects: SVY, WOM

Hera Health's President, Dr. Brian Iriye, to Present Study Results for the Society for Maternal-Fetal Medicine


Hera Health, a pioneering women's healthcare company, today announced acceptance to present a "late-breaking" study on pregnancy risk assessment at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meetingtm.

LAS VEGAS, Dec. 13, 2024 /PRNewswire-PRWeb/ -- Hera Health, a pioneering women's healthcare company, today announced acceptance to present a "late-breaking" study on pregnancy risk assessment at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meetingtm.

Dr. Brian Iriye, President of Hera Health and maternal-fetal medicine expert at the High Risk Pregnancy Center will present research results from the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME).

The Big Idea: Precision in Pregnancy Care

Dr. Brian Iriye, President of Hera Health and maternal-fetal medicine expert at the High Risk Pregnancy Center will present research results from the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME).

Why It Matters

Preterm birth remains a significant healthcare challenge:

Conference Information

The Pregnancy Meetingtm is an annual conference that brings together researchers and medical professionals in the field of maternal-fetal medicine.

About Hera Health

Hera Health is dedicated to advancing women's healthcare through innovative diagnostic and precision medicine approaches. Our mission is to empower healthcare providers with cutting-edge tools to improve maternal and neonatal health outcomes.

For more information, email [email protected] or visit www.hera-health.com.

Media Contact

Mike McCleney, Hera Women's Health, 1 617-543-3444, [email protected], https://hera-health.com/

SOURCE Hera Women's Health


These press releases may also interest you

at 20:24
Mary Alexander & Associates Files Second Lawsuit Against Dr. William Moore Thompson and Hoag Memorial
Mary Alexander & Associates filed a second lawsuit against disgraced Dr. William Moore Thompson and Hoag Memorial Hospital Presbyterian alleging sexual batter, sexual harassment, gender violence and more. The plaintiff in this matter (John Doe to...

at 20:11
Online Therapy Services Market size to increase by USD 64.09 billion between 2024 to 2029, Market Segmentation by Type, Application, Geography , Technavio
The global online therapy services market size is estimated to grow by USD 64.09 billion from 2025 to 2029, according to Technavio. The market is estimated to grow at a CAGR of 53.9% during the forecast period. The report provides a comprehensive...

at 19:56
One Week Update: California Animal Shelters Come Together to Help People, Pets Impacted by LA Fires
California's network of nearly 300 animal shelters and organizations are banding together to support families and animals impacted by the devastating Los Angeles fires. Nearly one week since the first fires, the situation remains critical:...

at 19:05
CN Bio Signs Strategic Partnership With Primetech Corporation to Establish Distribution Channel for OOC Solutions in Japan
CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced it has entered into a strategic partnership with Japanese life sciences research equipment...

at 19:05
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®)...

at 18:49
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
GRAIL, Inc. a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The...

More news about Health...


News published on and distributed by: